Market Closed -
Xetra
11:43:04 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
66.65
EUR
|
+0.83%
|
|
-1.77%
|
+96.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,021
|
3,072
|
1,139
|
451
|
1,278
|
2,510
|
-
|
-
|
Enterprise Value (EV)
1 |
3,791
|
2,299
|
470.7
|
-116.7
|
1,278
|
2,599
|
2,416
|
2,230
|
P/E ratio
|
-38.9
x
|
31.6
x
|
-2.17
x
|
-2.99
x
|
-6.15
x
|
-5.9
x
|
-32
x
|
-157
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
56
x
|
9.37
x
|
6.34
x
|
1.62
x
|
5.36
x
|
10.1
x
|
7.72
x
|
5.91
x
|
EV / Revenue
|
52.8
x
|
7.02
x
|
2.62
x
|
-0.42
x
|
5.36
x
|
10.5
x
|
7.43
x
|
5.25
x
|
EV / EBITDA
|
-37.3
x
|
64.4
x
|
-1.76
x
|
0.56
x
|
-5.28
x
|
-14.5
x
|
-23.4
x
|
-29.2
x
|
EV / FCF
|
-45.5
x
|
74.6
x
|
-0.97
x
|
0.32
x
|
-4.32
x
|
-8.79
x
|
-9.35
x
|
-18.6
x
|
FCF Yield
|
-2.2%
|
1.34%
|
-103%
|
316%
|
-23.2%
|
-11.4%
|
-10.7%
|
-5.38%
|
Price to Book
|
10.2
x
|
4.95
x
|
4.64
x
|
2.87
x
|
26.1
x
|
-13.8
x
|
4.79
x
|
3.55
x
|
Nbr of stocks (in thousands)
|
31,708
|
32,739
|
34,141
|
34,141
|
37,593
|
37,663
|
-
|
-
|
Reference price
2 |
126.8
|
93.82
|
33.35
|
13.21
|
34.00
|
66.65
|
66.65
|
66.65
|
Announcement Date
|
3/18/20
|
3/15/21
|
3/16/22
|
3/15/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
71.76
|
327.7
|
179.6
|
278.3
|
238.3
|
248.7
|
325.3
|
424.8
|
EBITDA
1 |
-101.7
|
35.69
|
-267.5
|
-210.2
|
-241.9
|
-179.8
|
-103
|
-76.3
|
EBIT
1 |
-107.9
|
27.36
|
-277.6
|
-220.7
|
-252.5
|
-384.7
|
-81.79
|
-0.8465
|
Operating Margin
|
-150.4%
|
8.35%
|
-154.57%
|
-79.32%
|
-105.96%
|
-154.69%
|
-25.15%
|
-0.2%
|
Earnings before Tax (EBT)
1 |
-106.5
|
22.49
|
-591.1
|
-319.6
|
-190.9
|
-431.7
|
-89.21
|
15.22
|
Net income
1 |
-103
|
97.89
|
-514.5
|
-151.1
|
-189.7
|
-430.1
|
-115.7
|
-31.38
|
Net margin
|
-143.56%
|
29.87%
|
-286.47%
|
-54.29%
|
-79.61%
|
-172.95%
|
-35.57%
|
-7.39%
|
EPS
2 |
-3.260
|
2.970
|
-15.40
|
-4.420
|
-5.530
|
-11.29
|
-2.083
|
-0.4239
|
Free Cash Flow
1 |
-83.24
|
30.81
|
-485.3
|
-368.6
|
-296.2
|
-295.8
|
-258.3
|
-119.9
|
FCF margin
|
-116.01%
|
9.4%
|
-270.19%
|
-132.48%
|
-124.29%
|
-118.93%
|
-79.42%
|
-28.23%
|
FCF Conversion (EBITDA)
|
-
|
86.34%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
31.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/20
|
3/15/21
|
3/16/22
|
3/15/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
269.7
|
52.9
|
41.5
|
59.4
|
95.8
|
81.6
|
62.3
|
53.2
|
63.8
|
59
|
64.69
|
50
|
51.68
|
53.01
|
35.93
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-79.34
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
163.5
|
-94.3
|
-68
|
-55.1
|
-29.3
|
-68.37
|
-69.5
|
-50.5
|
-51
|
-81.4
|
-382.3
|
-40.83
|
-39.51
|
-39.97
|
-29.22
|
-
|
Operating Margin
|
60.63%
|
-178.26%
|
-163.86%
|
-92.76%
|
-30.58%
|
-83.79%
|
-111.56%
|
-94.92%
|
-79.94%
|
-137.97%
|
-591%
|
-81.66%
|
-76.46%
|
-75.4%
|
-81.34%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-122.7
|
-
|
-123
|
-
|
-44.4
|
-74
|
-119.1
|
46.7
|
-312.6
|
-36.53
|
-46.53
|
-50.53
|
-
|
-
|
Net income
1 |
179.8
|
-
|
-122.7
|
-235
|
-122.9
|
329.4
|
-44.4
|
-74
|
-119.6
|
48.3
|
-315
|
-49.08
|
-56.95
|
-61.18
|
-
|
-
|
Net margin
|
66.66%
|
-
|
-295.66%
|
-395.62%
|
-128.29%
|
403.74%
|
-71.27%
|
-139.1%
|
-187.46%
|
81.86%
|
-486.87%
|
-98.16%
|
-110.2%
|
-115.42%
|
-
|
-
|
EPS
2 |
5.540
|
-11.16
|
-3.590
|
-6.880
|
-3.600
|
9.650
|
-1.300
|
-2.160
|
-3.500
|
1.220
|
-8.370
|
-1.203
|
-1.077
|
-1.394
|
-0.6600
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/5/20
|
3/16/22
|
5/4/22
|
8/3/22
|
11/16/22
|
3/15/23
|
5/3/23
|
8/9/23
|
11/15/23
|
3/13/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
89.3
|
-
|
-
|
Net Cash position
1 |
230
|
772
|
668
|
568
|
-
|
-
|
94.7
|
281
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.4965
x
|
-
|
-
|
Free Cash Flow
1 |
-83.2
|
30.8
|
-485
|
-369
|
-296
|
-296
|
-258
|
-120
|
ROE (net income / shareholders' equity)
|
-23.3%
|
19.3%
|
-65.5%
|
-75.1%
|
-184%
|
-
|
-453%
|
-
|
ROA (Net income/ Total Assets)
|
-19.9%
|
9.08%
|
-24.4%
|
-6.1%
|
-8.58%
|
-12.9%
|
-8.29%
|
-
|
Assets
1 |
517.6
|
1,078
|
2,108
|
2,477
|
2,211
|
3,325
|
1,395
|
-
|
Book Value Per Share
2 |
12.40
|
19.00
|
7.190
|
4.610
|
1.300
|
-4.830
|
13.90
|
18.80
|
Cash Flow per Share
|
-2.540
|
1.060
|
-14.40
|
-10.70
|
-
|
-
|
-
|
-
|
Capex
1 |
3.1
|
4.46
|
3.81
|
1.93
|
2.87
|
6.76
|
5.66
|
5.68
|
Capex / Sales
|
4.32%
|
1.36%
|
2.12%
|
0.69%
|
1.21%
|
2.72%
|
1.74%
|
1.34%
|
Announcement Date
|
3/18/20
|
3/15/21
|
3/16/22
|
3/15/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
66.65
EUR Average target price
58.71
EUR Spread / Average Target -11.91% Consensus |
1st Jan change
|
Capi.
|
---|
| +96.03% | 2.7B | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +28.07% | 12.14B | | +0.17% | 12.15B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|